Isoprenoids and Alzheimer's disease: A complex relationship
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Cholesterol metabolism has been linked to Alzheimer's disease (AD) neuropathology, which is characterized by amyloid plaques, neurofibrillary tangles and neuroinflammation. Indeed, the use of statins, which inhibit cholesterol and isoprenoid biosynthesis, as potential AD therapeutics is under investigation. Whether statins offer benefit for AD will be determined by the outcome of large, placebo-controlled, randomized clinical trials. However, their use as pharmacological tools has delineated novel roles for isoprenoids in AD. Protein isoprenylation regulates multiple cellular and molecular events and here we review the complex roles of isoprenoids in AD-relevant processes and carefully evaluate isoprenoid pathways as potential AD therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726 · cited 2×
“…between AD and cardiovascular disease with coronary artery disease, hypertension, and hypercholesterolemia, amongst others, being significant risk factors in AD (Kivipelto et al., 2002; Skoog et al., 1996; Soneira and Scott, 1996; Sparks et al., 1990; reviewed in Skoog and Gustafson, 2002).”
BackgroundDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“It has been previously demonstrated that an equilibrium exists between CNS and plasma Ah levels and that transport of Ah between the CNS and plasma may regulate brain Ah levels (DeMattos et al., 2001).”
BackgroundBillings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · cited 1×
“Intriguingly, in addition to extracellular plaques and intracellular Ah, Ah oligomers accumulate in AD brain (Gong et al., 2003; Kuo et al., 1996).”
BackgroundIntraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991 · cited 4×
“Not only is intraneuronal Ah42 detected at autopsy of patients with mild cognitive impairment (Gouras et al., 2000) but this form of Ah marks the initial site of amyloid accumulation in Down’s syndrome patients, who invariably succumb to AD-like dementia (Busciglio et al., 2002; Cataldo et al.,…”
BackgroundInfluentialLow cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10
Kojro, E., Gimpl, G., Lammich, S., März, W., & Fahrenholz, F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081612998 · Cited by 804
Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., & Gouras, G. K. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64463-x · Cited by 706
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618 · cited 1×
“Intriguingly, in addition to extracellular plaques and intracellular Ah, Ah oligomers accumulate in AD brain (Gong et al., 2003; Kuo et al., 1996).”
BackgroundThe Alzheimer's Aβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice
LaFerla, F. M., Tinkle, B. T., Bieberich, C. J., Haudenschild, C. C., & Jay, G. (1995) · Nature Genetics · doi:10.1038/ng0195-21 · Cited by 513
Oligomerization of Alzheimer's β-Amyloid within Processes and Synapses of Cultured Neurons and Brain
Takahashi, R. H., Almeida, C. G., Kearney, P. F., Yu, F., Lin, M. T., Milner, T. A., & Gouras, G. K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5167-03.2004 · Cited by 445 · cited 1×
“…to suggest that this form of Ah is involved in some of the early stages of AD development (Billings et al., 2005; Busciglio et al., 2002; Cataldo et al., 2004; Gouras et al., 2000; LaFerla et al., 1995; Magrane et al., 2004; Mori et al., 2002; Skovronsky et al., 1998; Takahashi et al., 2002, 2004).”
BackgroundAssociation of γ-Secretase with Lipid Rafts in Post-Golgi and Endosome Membranes
Vetrivel, K. S., Cheng, H., Lin, W., Sakurai, T., Li, T., Nukina, N., Wong, P. C., Xu, H., & Thinakaran, G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407986200 · Cited by 413
Cataldo, A. M., Petanceska, S., Terio, N. B., Peterhoff, C. M., Durham, R., Mercken, M., Mehta, P. D., Buxbaum, J., Haroutunian, V., & Nixon, R. A. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.027 · Cited by 363
Rodriguez-Viciana, P., Sabatier, C., & McCormick, F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.11.4943-4954.2004 · Cited by 327 · cited 4×
“The Ras GTPase superfamily is composed of over a 150 members, subdivided into five major branches, namely the small Arf/Sar and Ran families, and the larger Ras, Rho and Rab GTPase families (Rodriguez-Viciana et al., 2004; reviewed in Takai et al., 2001).”
BackgroundInfluentialNonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß 42 by Inhibiting Rho
Zhou, Y., Su, Y., Li, B., Liu, F., Ryder, J. W., Wu, X., Gonzalez-DeWhitt, P. A., Gelfanova, V., Hale, J. E., May, P. C., et al. (2003) · Science · doi:10.1126/science.1090154 · Cited by 316 · cited 12×
“, 2005) and affect the specificity of gsecretase cleavage to modulate Ah42 secretion (Zhou et al., 2003).”
BackgroundInfluentialBenjannet, S., Elagoz, A., Wickham, L., Mamarbachi, M., Munzer, J. S., Basak, A., Lazure, C., Cromlish, J. A., Sisodia, S., Checler, F., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009899200 · Cited by 301 · cited 1×
“Intriguingly, in the context of AD, it is interesting to note that BACE1 undergoes palmitoylation, and it has been speculated that this modification serves primarily to direct the protein to discrete membrane microdomains (Benjannet et al., 2001).”
BackgroundSkovronsky, D. M., Doms, R. W., & Lee, V. M.-Y. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.4.1031 · Cited by 290 · cited 4×
“…to suggest that this form of Ah is involved in some of the early stages of AD development (Billings et al., 2005; Busciglio et al., 2002; Cataldo et al., 2004; Gouras et al., 2000; LaFerla et al., 1995; Magrane et al., 2004; Mori et al., 2002; Skovronsky et al., 1998; Takahashi et al., 2002, 2004).”
BackgroundInfluentialThe role of Aβ42 in Alzheimer's disease
Younkin, S. G. (1998) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(98)80035-1 · Cited by 282 · cited 1×
“Furthermore, this species appears toxic to neurons both in vitro and in vivo (reviewed in Selkoe, 2001; Younkin, 1998).”
BackgroundCholesterol and the Biology of Alzheimer's Disease
Wolozin, B. (2004) · Neuron · doi:10.1016/s0896-6273(03)00840-7 · Cited by 275
Mechanisms of Statin-mediated Inhibition of Small G-protein Function
Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A., & Landreth, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505268200 · Cited by 235 · cited 2×
“These effects culminate in the functional inhibition of Rho-family GTPases and thus a mechanism by which statins attenuate Ah-stimulated inflammation was proposed (Cordle et al., 2005).”
BackgroundA dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity
Guo, L., LaDu, M. J., & Van Eldik, L. J. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:205 · Cited by 175
Modulation of Statin-Activated Shedding of Alzheimer APP Ectodomain by ROCK
Pedrini, S., Carter, T. L., Prendergast, G., Petanceska, S., Ehrlich, M. E., & Gandy, S. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020018 · Cited by 154 · cited 13×
“metabolism (Cole et al., 2005; Pedrini et al., 2005; Zhou et al., 2003), glial activation (Bi et al.”
BackgroundInfluentialNSAIDs and incident Alzheimer’s disease. The Rotterdam study
In ’t Veld, B. A., Launer, L. J., Hoes, A. W., Ott, A., Hofman, A., Breteler, M. M. B., & Stricker, B. H. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00096-7 · Cited by 145
Dolev, I., & Michaelson, D. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404458101 · Cited by 102 · cited 2×
“At a molecular level, the association between ApoE and increased AD risk remains to be explicitly determined although it has been reported that ApoE is essential for two centrally important factors in plaque formation, namely Ah fibrillization and deposition (Bales et al., 1999; Dolev and Michaelson, 2004).”
BackgroundPresenilins interact with Rab11, a small GTPase involved in the regulation of vesicular transport
Dumanchin, C. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.7.1263 · Cited by 99 · cited 2×
“Furthermore, a physical association between PS1 and Rab11 has been demonstrated (Dumanchin et al., 1999) and the levels of Rab8 are reduced in PC12D cells that express mutant, but not wild type, PS-1 (Kametani et al., 2004).”
BackgroundFunction and Dysfunction of the Presenilins
Sisodia, S. S., Kim, S. H., & Thinakaran, G. (1999) · The American Journal of Human Genetics · doi:10.1086/302475 · Cited by 76 · cited 2×
“Protein isoprenylation regulates multiple cellular and molecular events and here we review the complex roles of isoprenoids in AD-relevant processes and carefully evaluate isoprenoid pathways as potential AD therapeutic targets.”
BackgroundMethod
Cited by
Linking lipids to Alzheimer's disease: cholesterol and beyond
Di Paolo, G., & Kim, T.-W. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3012 · Cited by 972
Statins: Mechanisms of neuroprotection
van der Most, P. J., Dolga, A. M., Nijholt, I. M., Luiten, P. G. M., & Eisel, U. L. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.02.002 · Cited by 268
“On the other hand, many in vitro studies have reported that depletion of isoprenoids also reduces Ab-production (Cole and Vassar, 2006; Ostrowski et al., 2007; Won et al., 2008).”
Tamboli, I. Y., Barth, E., Christian, L., Siepmann, M., Kumar, S., Singh, S., Tolksdorf, K., Heneka, M. T., Lütjohann, D., Wunderlich, P., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149468 · Cited by 218
Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis
Wood, W. G., Li, L., Müller, W. E., & Eckert, G. P. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12637 · Cited by 194
Butterfield, D. A., Barone, E., & Mancuso, C. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.007 · Cited by 80
“Through the inhibition of HMG-CoA reductase activity, statins reduce the formation of L-mevalonic acid and subsequent prevention of isoprenoid synthesis [4,7,8].”
Background
Metadata
- Authors
- Cole, S. L., & Vassar, R.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 22
- Issue
- 2
- Pages
- 209-222
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2084820723
- Cited by
- 71
- References
- 27
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.